InMed Pharmaceuticals News

Press Releases

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

May 14, 2020

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

May 12, 2020

Notice of Telephone Scam Impersonating InMed

May 8, 2020

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

May 8, 2020

InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference

May 7, 2020

InMed and Almac Group Developing Improved Cannabinoid Production Methods

May 5, 2020

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

April 30, 2020

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

April 1, 2020

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

March 24, 2020

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

March 20, 2020

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

March 10, 2020

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

February 14, 2020

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

February 7, 2020

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

January 21, 2020

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

January 20, 2020

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

January 16, 2020

InMed Announces Election of Directors

January 10, 2020

InMed Pharmaceuticals to Present at the Biotech Showcase Conference

January 8, 2020

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

December 9, 2019

InMed Pharmaceuticals to Present at the Cowen Conference

November 11, 2019

Management

Learn More

Board of Directors

Learn More

Scientific Advisory Board

Learn More

Press Releases

InMed Pharmaceuticals Reports Third Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Files PCT Patent Application for Neuroprotection in Glaucoma

Notice of Telephone Scam Impersonating InMed

InMed Pharmaceuticals to Report Third Quarter Fiscal 2020 Financial Results and Business Update on May 14, 2020

InMed to Present at Canaccord Genuity’s 4th Annual Cannabis Conference

InMed and Almac Group Developing Improved Cannabinoid Production Methods

InMed Receives CTA Approval for Second Phase 1 Clinical Trial with INM-755

InMed Announces Completion of Initial Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial

InMed Provides Update on Operations in Response to the COVID-19 Global Outbreak

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

InMed Pharmaceuticals Reports Second Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

InMed Pharmaceuticals to Report Second Quarter Fiscal 2020 Financial Results and Business Update on February 14, 2020

InMed Expands on Announcement of Cannabinol (CBN) Therapeutic Leadership with New Website Content and CEO Interview

InMed First to Advance Cannabinol (CBN) into Therapeutic Clinical Trials

InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

InMed Announces Election of Directors

InMed Pharmaceuticals to Present at the Biotech Showcase Conference

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

InMed Pharmaceuticals to Present at the Cowen Conference

Management

Board of Directors

Scientific Advisory Board

Investor Alerts

Sign up to receive emails from InMed Pharmaceuticals